4(S)-<(tert-butyldimethylsilyl)oxy>-5(S)-<(tert-butyloxycarbonyl)amino>-2(S)-isopropyl-7-methyloctanoic acid | 103335-80-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4(S)-<(tert-butyldimethylsilyl)oxy>-5(S)-<(tert-butyloxycarbonyl)amino>-2(S)-isopropyl-7-methyloctanoic acid
• 英文别名: (2S,4S,5S)-4-[tert-butyl(dimethyl)silyl]oxy-7-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-propan-2-yloctanoic acid
• CAS: 103335-80-4
• 化学式: C₂₃H₄₇NO₅Si
• 分子量: 445.715
• InChiKey: WHIVNRKSGTVPHM-FHWLQOOXSA-N

物化性质

• 沸点：
  512.5±45.0 °C(Predicted)
• 密度：
  0.970±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.06
• 重原子数：
  30
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4(S)-<(tert-butyldimethylsilyl)oxy>-5(S)-<(tert-butyloxycarbonyl)amino>-2(S)-isopropyl-7-methyloctanoic acid 在 盐酸 、 diethylphosphoryl cyanide 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  肾素抑制肽。β-天冬氨酰残基可替代P-2位点的组氨酸残基。

  摘要：

  为了减小先前制备的肾素抑制肽的尺寸并增加其亲水性，推测可能通过与人肾素的潜在氢键结合来利用肾素酶的皮瓣区域上的极性Thr-84。 P-2位点抑制肽的极性功能。有人提出，带有羧酸基团的β-天冬氨酰残基可以替代P-2位的组氨酸残基。用β-天冬氨酰残基制备了一系列肾素抑制肽，以探测所得肽的结构-活性关系。可以实现在亚纳摩尔范围内的活性的强抑制肽。还进行了分子建模以研究酶活性位点与新抑制剂之间的相互作用，并提出了这些配体与酶结合的可能方式。通过该建模研究，提出了Ser-229在抑制剂结合构象异构体活性位点的作用。在类似物研究中进一步指出，苹果酸残基（β-天冬氨酸残基的氧类似物）可能导致同类肽的抑制能力进一步提高。可以制备小的肾素抑制剂，例如分子量为535且没有α-氨基酸残基的化合物XII，并在纳摩尔范围内表现出抑制肾素的活性。提示Ser-229在抑制剂结合构象的活性位点上的作用。在类似物研究中进一

  DOI：

  10.1021/jm00167a009
• 作为产物：
  描述：

  (2R,4S,5S)-2-(2-propyl)-4-hydroxy-5-<(tert-butyloxycarbonyl)amino>-7-methyloctanoic acid δ-lactone 在 sodium hydroxide 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 4(S)-<(tert-butyldimethylsilyl)oxy>-5(S)-<(tert-butyloxycarbonyl)amino>-2(S)-isopropyl-7-methyloctanoic acid
  参考文献：
  名称：

  Design of Substrate-Based Inhibitors of Human β-Secretase

  摘要：

  By use of the effectively cleaved beta-secretase (BACE) substrate (1), incorporation of a statine in P-l resulted in a weak inhibitor 13 of the enzyme. Further substitution of P-1'-Asp by P-1'-Val in 13 results in a potent inhibitor 22 of BACE. Removal of the P-10-P-5 residues on the N-terminal part of inhibitor 22 resulted in no loss of potency (23). C-terminal truncations of inhibitor 22 generally led to significant loss of potency.

  DOI：

  10.1021/jm0155695

文献信息

• Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo
  作者：Suvit Thaisrivongs、Donald T. Pals、Douglas W. Harris、Warren M. Kati、Steve R. Turner

  DOI：10.1021/jm00160a049

  日期：1986.10

  A structure-activity analysis of peptides containing backbone C alpha-methyl and N alpha-methyl modifications led to the discovery of potent renin inhibitors with high metabolic stability. In vitro, Boc-Pro-Phe-N alpha-MeHis-Leu psi-[CHOHCH2]Val-Ile-Amp (XII) is a potent inhibitor of human plasma renin with IC50 of 0.26 nM. It is a much weaker inhibitor of other aspartic proteases such as porcine pepsin

  对含有主链Cα-甲基和Nα-甲基修饰的肽进行结构活性分析导致发现了具有高代谢稳定性的有效肾素抑制剂。在体外，Boc-Pro-Phe-Nα-MeHis-Leupsi- [CHOHCH2] Val-Ile-Amp（XII）是人血浆肾素的有效抑制剂，IC50为0.26 nM。它是其他天冬氨酸蛋白酶（如猪胃蛋白酶或牛组织蛋白酶D）的弱得多的抑制剂（IC50 = 6 microM）。已表明它不会被大鼠肝匀浆制剂降解。在体内，它抑制了血浆血浆肾素的活性并降低了呋塞米治疗的食蟹猴的血压。静脉注射5 mg / kg时，明显的降压反应持续3个小时以上。
• [EN] NOVEL SULFONE AMIDE DERIVATIVES CAPABLE OF INHIBITING BACE<br/>[FR] NOUVEAUX DERIVES SULFONAMIDE CAPABLES D'INHIBER BACE
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2005030709A1

  公开（公告）日：2005-04-07

  The present invention relates to novel derivatives of sulfone amide of Formula 1 as defined in this disclosure which inhibit the activity of BACE (or beta-secretase). These sulfone amide derivatives are useful for the treatment and prevention of Alzheimer's disease and related diseases caused by production of beta-amyloid, by inhibiting the activity of BACE.

  本发明涉及本公开中定义的式1的磺酰脒衍生物，该衍生物抑制BACE（或β-分泌酶）的活性。这些磺酰脒衍生物可用于治疗和预防由β-淀粉样蛋白产生引起的阿尔茨海默病及相关疾病，通过抑制BACE的活性。
• Renin inhibitors. Design of angiotensinogen transition-state analogs containing novel (2R,3R,4R,5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid
  作者：Suvit Thaisrivongs、Donald T. Pals、Lisa T. Kroll、Steve R. Turner、Fu Son Han

  DOI：10.1021/jm00389a004

  日期：1987.6

  5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid residue at the scissile site are shown to be potent inhibitors of human plasma renin. The glycol moiety in this novel acid, dihydroxyethylene isostere, is suggested to act as a transition-state analogue and mimics the tetrahedral intermediate formed during the enzyme-catalyzed hydrolysis of the peptidic bond.

  2（R）-[5（R）-[1（S）-[（叔丁氧羰基氨基）氨基] -3-甲基丁基] -2,2-二甲基-4（R-二氧戊环）-的高立体选择性合成描述了3-甲基丁酸。这是一种适当保护的羧酸，可用作制备肾素抑制肽的中间体。血管紧张素原类似物如肽IX和X在易裂位点含有二肽等排物（2R，3R，4R，5S）-5-氨基-3,4-二羟基-2-异丙基-7-甲基辛酸残基人血浆肾素的有效抑制剂。该新型酸二羟基乙烯等排物中的二醇部分被建议充当过渡态类似物，并模仿在酶催化的肽键水解过程中形成的四面体中间体。
• .alpha.-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model
  作者：Suvit Thaisrivongs、Donald T. Pals、Judy A. Lawson、Steve R. Turner、Douglas W. Harris

  DOI：10.1021/jm00386a016

  日期：1987.3

  A structure-activity analysis of peptides containing backbone C alpha-methyl modification at the P4 site of the angiotensinogen sequence led to the discovery of potent renin inhibitors with apparent in vitro metabolic stability. Boc-alpha-MePro-Phe-His-Leu psi[CHOHCH2]Val-Ile-Amp dicitrate (Va) is a potent inhibitor of human plasma renin with an IC50 value of 1.8 nM. This peptide was shown not to be degraded in vitro by chymotrypsin, elastase, pepsin, and a rat liver homogenate preparation. It is also a potent inhibitor of hog renin with an IC50 value of 1.6 nM and was shown to elicit in vivo activity and cause dose-dependent hypotensive responses when given intravenously to anesthetized ganglion-blocked, hog renin infused rats.
• On a Possible Neutral Charge State for the Catalytic Dyad in β-Secretase When Bound to Hydroxyethylene Transition State Analogue Inhibitors
  作者：Fredy Sussman、José M. Otero、M. Carmen Villaverde、Marian Castro、José L. Domínguez、Lucía González-Louro、Ramón J. Estévez、J. Carlos Estévez

  DOI：10.1021/jm101568y

  日期：2011.4.28

  beta-Secretase is one of the aspartic proteases involved in the formation of amyloid plaques in Alzheimer's disease patients Our previous results using a combination of surface plasmon resonance experiments with molecular Modeling calculations: suggested that the Asp dyad in beta-secretase bound to hydroxylethylene containing inhibitors adopts a neutral charged state. In this work, we show that the Asp dyad diprotonated state reproduced the binding ranking of a set of these inhibitors better than alternative protonation states.